The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). Zepbound ... between our sales teams and authors ...

Eli Lilly, the maker of Zepbound, is emerging as a market leader with strong growth in revenue and a robust drug pipeline. Elevated implied volatility (IV Rank ~40) makes Lilly an ideal candidate for ...

(RTTNews) - Eli Lilly and Company (LLY), Tuesday announced an agreement regarding the acquisition of SiteOne Therapeutics, Inc., a private biotechnology company, for upto $1 billion in cash ...

MILAN, May 27 (Reuters) - The United States has warned Pirelli (PIRC.MI), opens new tab that sales of vehicles fitted with its data-collecting technology could be restricted due to concerns over ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

In recent months, the pharmaceutical companies — Novo Nordisk, Wegovy’s manufacturer, and Lilly, Zepbound’s manufacturer — have launched new programs to increase access at a lower cost. For example, ...

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale ... Zepbound and Mounjaro from competitor Eli Lilly.